Search Medical Condition
Please enter condition
Please choose location

Deep Vein Thrombosis Clinical Trials

A listing of Deep Vein Thrombosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (29) clinical trials

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately ...

Phase

Aqua Therapy in Deep Venous Thrombosis and Insufficiency

Post-thrombotic syndrome (PTS) develops in approximately 25-60% of patients with acute lower extremity deep venous thrombosis (DVT) depending on severity, chronicity, anatomic level of involvement and efficacy of anticoagulation.The frequency increases with occlusive iliac venous thrombosis. PTS results in significant morbidity and a staggering toll on health careresources . PTS ...

Phase N/A

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Chronic portal vein thrombosis (PVT) is a rare disease, affecting young patients, characterized by permanent obstruction of the portal vein trunk causing portal hypertension. In 60-70% of cases it is related to high risk, moderate or mild prothrombotic risk factors. Accordingly, there are 2 types of complications from PVT :(i) ...

Phase

Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)

The CACTUS-PTS study will compare anticoagulant treatment for 6 weeks versus placebo in acute, symptomatic distal DVT. Patients will be randomized to receive either a six-week period of LMWH at therapeutic dosage or a six-week period of placebo. All patients will be treated with elastic compression stockings and followed-up with ...

Phase

Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis

BACKGROUND. Currently there is no consensus on the optimal duration of antithrombotic therapy in cancer patients experiencing a first episode of deep vein thrombosis (DVT) of lower limbs. Recent guidelines suggest that patients with active cancer suffering of DVT of the lower limbs should be treated for at least six ...

Phase

Genetic Determinants of Warfarin Anticoagulation Effect

The response to warfarin varies greatly among individuals. Some of this variability can be ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the metabolism of S warfarin. In addition genetic polymorphism in other genes (i.e. VKORC1, factor VII) have been shown to account for some ...

Phase N/A

Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes

Clinical Study Protocol Failed Retrieval of Inferior Vena Cava (IVC) filters: long-term outcomes Study Objective To evaluate the long term outcomes for failed IVC retrieval. Background Long-term placement of IVC filters is not without complication. Descosous et al. demonstrated that those patients with IVC filter placement had greater than three ...

Phase N/A

Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism

Research design: multicenter collaboration, prospective, non-interventional, observational research Research outline: Registration period: Dec 2016 (after ethics committee approval) to May 2018 (1 year and 6 months) Investigation period: Dec 2016 (after ethics committee approval) to Nov 2019 (At least 1 year and 6 months) Target number of participants: 1,000 participants ...

Phase N/A

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified. Patients with persistent atrial fibrillation (>12 hours) or recurrent sustained atrial fibrillation (>2 episodes of atrial fibrillation lasting longer than 30 minutes) will be candidates for inclusion. Upon ...

Phase

Angel Catheter Post Market Registry

The Registry population will include all consecutive patients in whom the Angel® Catheter is placed at participating sites. Information about the use of the catheter will be collected from placement through three days after device removal, or through death or discharge, whichever occurs first. Date of discharge/transfer from the Critical ...

Phase N/A